throbber
Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 1 of 15 PAGEID #: 26
`
`3:19-cr-68
`
`Judge Walter H. Rice
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 2 of 15 PAGEID #: 27
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 2 0f 15 PAGEID #: 27
`
`GENERAL ALLEGATIONS AND TERMINOLOGY
`
`6.
`
`The Controlled Substances Act
`
`(“GSA”) governs the manufacture,
`
`distribution, and dispensation of controlled substances in the United States. The
`
`CSA and the Code of Federal Regulations (“CFR”) contain definitions relevant to
`
`this Indictment, some of which are set forth below.
`
`7.
`
`The term “controlled substance” means a drug or other substance, or
`
`immediate precursor, included in Schedule I, II, III, IV and V, as designated by
`
`Title 21, United States Code, Section 802(c)(6), and the CFR.
`
`8.
`
`The term “Schedule II” means the drug or other substance has a high
`
`potential for abuse; the drug has a currently accepted medical use with severe
`
`restrictions; and abuse of the drug or other substance may lead to severe
`
`psychological or physical dependence.
`
`9.
`
`The term “dispense” means to deliver a controlled substance to an
`
`ultimate user or research subject by, or pursuant
`
`to the lawful order of, a
`
`practitioner, including the prescribing and administering of a controlled substance.
`
`10.
`
`The term “distribute” means to deliver (other than by administering or
`
`dispensing) a controlled substance.
`
`11.
`
`The term “practitioner” means a medical doctor, physician, or other
`
`individual licensed, registered, or otherwise permitted, by the United States or the
`
`jurisdiction in which she or he practices, to dispense a controlled substance in the
`
`course of profit.
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 3 of 15 PAGEID #: 28
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 3 0f 15 PAGEID #: 28
`
`12.
`
`The term “pharmacist” means any pharmacist licensed by a State to
`
`dispense controlled substances, and shall include any person authorized by a State
`
`to dispense controlled substances under the supervision of a pharmacist licensed by
`
`such state.
`
`13.
`
`The Drug Enforcement Administration (“DEA”)
`
`issues registration
`
`numbers to qualifying doctors and pharmacies, who become authorized to dispense
`
`Schedule II, 11,
`
`IV, and V controlled substances. To issue a prescription for a
`
`controlled substance, a doctor or pharmacy must have a DEA registration number
`
`for each location in which they are dispensing medicine per state where dispensing
`
`controlled substances.
`
`14.
`
`A prescription for a controlled substance violates the CSA and CFR if
`
`it is issued beyond the bounds of medical practice or is not for a legitimate medical
`
`purpose in the usual course of a professional practice.
`
`15.
`
`The term “dosage” is the amount, frequency, and number of doses of
`
`medication authorized by a practitioner, who has been issued a DEA registration
`
`number.
`
`16.
`
`The term “prescription” means an order
`
`for medication which is
`
`dispensed to or for an ultimate user but does not include an order for medication
`
`which is dispensed for immediate administration to the ultimate user.
`
`17.
`
`The purpose of a urine test
`
`is
`
`to determine if the prescribed
`
`medications and/or illicit drugs (e.g., cocaine) is in the patient’s urine.
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 4 of 15 PAGEID #: 29
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 4 0f 15 PAGEID #: 29
`
`CONTROLLED SUBSTANCES RELEVANT TO THE INDICTMENT
`Endocet is a brand name pill that contains oxycodone, a Schedule II
`
`18.
`
`controlled substance.
`
`19.
`
`Oxycodone is a Schedule II controlled substance.
`
`20. Methadone iS a Schedule II controlled substance.
`
`21.
`
`Hydrocodone is a Schedule II controlled substance.
`
`22. Morphine is a Schedule II controlled substance.
`
`23.
`
`24.
`
`Fentanyl is a Schedule II controlled substance.
`
`Xanax is a brand name pill that contains alprazolam, a Schedule IV
`
`controlled substance.
`
`Soma is a brand name pill that contains carisoprodol. As of January
`25.
`11, 2012, Carisoprodol is a Schedule IV controlled substance.
`
`MORRIS BROWN’S ILLEGAL DISTRIBUTION OF CONTROLLED SUBSTANCES
`Defendant MORRIS BROWN Obtained his medical license in the State
`
`26.
`
`of Ohio on or around 1975, Specializing in family medicine.
`
`27.
`
`medical services through his company DAYTON PRIMARY & URGENT CARE
`
`CENTER, INC. (“DAYTON PRIMARY”),
`
`located at 301 West First Street, Suite
`
`100, in Dayton Ohio, in the Southern District of Ohio.
`
`28.
`
`On or about 2006, DAYTON PRIIWARY became a Domestic Limited
`
`Liability Company in the State of Ohio.
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 5 of 15 PAGEID #: 30
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 5 0f 15 PAGEID #: 30
`
`29. MORRIS BROWN was registered with federal and state authorities to
`
`prescribe schedule II-V controlled substances.
`
`30.
`
`During patient visits, MORRIS BROWN often provided only a cursory
`
`medical examination of patients before agreeing to provide them Schedule II
`
`controlled substance prescriptions.
`
`81.
`
`In many instances, MORRIS BROWN provided large amounts of
`
`controlled substance prescription medications to patients that BROWN knew or had
`
`a reasonable cause to believe were drug addicts or diverting/selling the medication.
`
`32. MORRIS BROWN rarely,
`
`if ever, counseled patients regarding
`
`alternative treatments for pain, such as physical therapy, psychological or addiction
`
`counseling, or surgery.
`
`33.
`
`As part of the patient “visit,” MORRIS BROWN, or others in his office,
`
`administered urine tests for the purpose of disguising the lack of any legitimate
`
`medical purpose for
`
`the prescription, dispensing, or distribution of controlled
`
`substances. MORRIS BROWN ignored the results of the urine tests and continued
`
`to provide controlled substances to patients.
`
`34. MORRIS BROWN also ignored information provided to him by other
`
`medical professionals about other patients exhibiting drug-seeking behavior, and
`
`continued to provide controlled substances to patients.
`
`35. MORRIS BROWN distributed and dispensed, and caused to be
`
`distributed and dispensed, controlled substances to many of his patients not for a
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 6 of 15 PAGEID #: 31
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 6 0f 15 PAGEID #: 31
`
`legitimate medical purpose and outside the scope of professional practice. Despite
`
`some aspects of legitimate medical practice, MORRIS BROWN ran what was, in
`
`essence, a “pill mill”— MORRIS BROWN’S primary method of treating nearly all of
`
`his patients was
`
`to prescribe highly addictive opioid controlled substances,
`
`including, but not
`
`limited to, endocet, oxycodone, methadone, hydrocodone,
`
`morphine, fentanyl, carisoprodol, and alprazolam.
`
`36. MORRIS BROWN continued these prescriptions even after learning
`
`that some of his patients had experienced overdoses, and in some cases, deaths.
`
`37.
`
`On or
`
`about October
`
`1,
`
`1986,
`
`defendant MORRIS BROWN
`
`incorporated MORRIS L. BROWN, M.D. & ASSOCIATES, INC. as a professional
`
`corporation (“BROWN & ASSOCIATES”) in the State of Ohio.
`
`38.
`
`On or about August 2005, BROWN & ASSOCIATES purchased
`
`property located at 301 West First Street, Suite 100, Dayton, Ohio.
`
`39.
`
`Between on or about 2008 and on or about 2017, DAYTON PRIMARY
`
`operated at the 301 West First Street, Suite 100, Dayton, Ohio location, owned by
`
`MORRIS BROWN.
`
`40.
`
`Between on or about 2008 and on or about 2017, MORRIS BROWN
`
`leased some of the space within at 301 West First Street, Suite 100, Dayton, Ohio to
`
`DAYTON PHARMACY.
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 7 of 15 PAGEID #: 32
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 7 0f 15 PAGEID #: 32
`
`41.
`
`On or about 2015, BROWN, began accepting approximately $5000 per
`
`month from the owners of DAYTON PHARMACY disguised as “rent” to allow them
`
`to continue to operate the pharmacy.
`
`42. MORRIS BROWN obtained substantial income and resources from his
`
`distribution and dispending Of controlled substances.
`
`UNLAWFUL DISTRIBUTION AND DISPENSING OF CONTROLLED
`
`COUNTS ONE THROUGH 81X
`
`THE GRAND JURY FURTHER CHARGES THAT:
`
`SUBSTANCES
`
`[21 U.S.C. § 841]
`
`43.
`
`Paragraphs
`
`1
`
`through 42 of
`
`the Indictment are realleged and
`
`incorporated by reference as though fully set forth herein.
`
`On or about the dates set forth below, in the Southern District Of Ohio, and
`
`elsewhere,
`
`the defendant MORRIS BROWN, a physician authorized to dispense
`
`controlled substances, did knowingly, intentionally, and unlawfully dispense and
`
`distribute, and cause to be dispensed and distributed, outside the usual course of
`
`professional practice and not for a legitimate medical purpose,
`
`the Schedule II
`
`controlled substances, as listed below:
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 8 of 15 PAGEID #: 33
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 8 0f 15 PAGEID #: 33
`
`
`
`Count
`
`Endocet,
`Methadone
`
`
`Controlled
`Patient Approximate
`Date of
`Substance(s)
`
`
`Prescription
`
`1 2/2/2015
`Endocet
`RA
`
`
`2/17/2016
`Hydrocodone,
`
`
`Morphine
`
`2/23/2016
`
`
`
`
`Alprazolam,
`
`
`
`
`Oxycodone
`Methadone,
`3/23/2016
`
`Endocet
`
`
`
`2/28/2017
`Oxycodone,
`
`Fentanyl
`
`
`
`
`
`9/12/2016
`
`Endocet,
`
`Methadone,
`
`In violation of 21 U.S.C. §§ 841(a)(1), 841(b)(1)(C) and 18 U.S.C. § 2.
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 9 of 15 PAGEID #: 34
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 9 0f 15 PAGEID #: 34
`
`MAINTENANCE OF PREMISES FOR UNLAWFUL DISTRIBUTION OR
`
`COUNT SEVEN
`
`DISPENSING
`
`[21 U.S.C. § 856]
`
`44.
`
`Paragraphs
`
`1
`
`through 42 of
`
`the Indictment are realleged and
`
`incorporated by reference as though fully set forth herein.
`
`45.
`
`Beginning on or around January 2012 and continuing through on or
`
`around November 2017, in the Southern District of Ohio and elsewhere, defendant
`
`MORRIS BROWN, did knowingly and intentionally open,
`
`lease, rent, use, and
`
`maintain a place, namely the premises located at 801 West First Street, Suite 100,
`
`Dayton Ohio, for the purpose of distributing Schedule II controlled substances, and
`
`other controlled substances
`
`Allin violation of 21 U.S.C. §§ 856(a)(1), 856(a)(2) and 18 U.S.C. § 2.
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 10 of 15 PAGEID #: 35
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 10 0f 15 PAGEID #: 35
`
`CONSPIRACY TO OBTAIN CONTROLLED SUBSTANCES BY
`
`MISREPRESENTATION, FRAUD, FORGERY, DECEPTION, 0R. SUBTERFUGE
`
`COUNT EIGHT
`
`THE GRAND JURY FURTHER CHARGES THAT:
`
`[21 U.S.C. § 846}
`
`46.
`
`Paragraphs
`
`1
`
`through 42 of
`
`the Indictment are realleged and
`
`incorporated by reference as though fully set forth herein.
`
`47.
`
`Beginning on or about January 1, 2012, within the Southern District of
`
`Ohio, and elsewhere, the defendants, ISMAIL ABUHANIEH, MAHMOUD RIFAI,
`
`MAHMOUD ELMIARI, YOHANNES TINSAE, and others known and unknown to
`
`the grand jury, did knowingly,
`
`intentionally, and unlawfully combine, conspire,
`
`confederate, and agree together with others known and unknown to the grand jury
`
`to knowingly,
`
`intentionally, and unlawfully acquire and obtain possession of
`
`controlled substances by misrepresentation,
`
`fraud,
`
`forgery,
`
`deception,
`
`and
`
`subterfuge.
`
`In violation of Title 21, United States Code, Section 846 and Title 21,
`
`United States Code, Sections 843(a)(3).
`
`OBJECT OF THE CONSPIRACY
`
`The object of the conspiracy included, but was not limited to, the following:
`
`48.
`
`For defendants to enrich themselves by obtaining proceeds of the
`
`conspiracy derived from DAYTON PHARMACY’S sale of controlled substances to
`
`customers.
`
`10
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 11 of 15 PAGEID #: 36
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 11 0f 15 PAGEID #: 36
`
`49.
`
`During the course and in furtherance of the conspiracy, in or about
`
`MANNER AND lVlEANS
`
`June 2008, defendant ISMAIL ABUHANIEH incorporated Haya LLC with the Ohio
`
`Secretary of State with an address of 301 West First Street, Suite 100, Dayton,
`
`Ohio. Haya LLC did business under the name DAYTON PHARMACY.
`
`50.
`
`During the course and in furtherance of the conspiracy, in or about
`
`August 2008, MAHMOUD RIFAI applied for and was granted a DEA registration
`
`for DAYTON PHARMACY to allow DAYTON PHARMACY to dispense controlled
`
`substances, including Schedule II controlled substances.
`
`51.
`
`During the course and in furtherance of the conspiracy,
`
`ISMAIL
`
`ABUHANIEH and MAHMOUD RIFAI held themselves to be the owners of
`
`DAYTON PHARMACY located at 301 West First Street, Suite 100 in Dayton, Ohio.
`
`52.
`
`During the course and in furtherance of the conspiracy, between
`
`approximately 2010 and 2015, YOHANNES TINSAE was the pharmacist in charge
`
`at DAYTON PHARMACY located at 301 West First Street, Suite 100 in Dayton,
`
`Ohio.
`
`53.
`
`During the course and in furtherance of the conspiracy, between
`
`approximately on or about 2010 and on or about 2017, MAHMOUD ELMIARI was
`
`the pharmacy manager at DAYTON PHARMACY located at 301 West First Street,
`
`Suite 100 in Dayton, Ohio.
`
`11
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 12 of 15 PAGEID #: 37
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 12 0f 15 PAGEID #: 37
`
`54.
`
`During the course and in furtherance of the conspiracy,
`
`ISMAIL
`
`ABUHANIEH incorporated DAYTON PHARIVIACY as a limited liability company in
`
`the State of Ohio.
`
`55.
`
`During the course and in furtherance of the conspiracy, on or about
`
`August 2008, MAHMOUD RIFAI applied for, and was granted, a DEA license to
`
`dispense and distribute controlled substances,
`
`including Schedule II controlled
`
`substances, for DAYTON PHARMACY. On or about May 2017, MAHMOUD RIFAI
`
`reapplied using the DEA website for DAYTON PHARMACY’S DEA license.
`
`56.
`
`During the course and in furtherance of the conspiracy,
`
`ISMAIL
`
`ABUHANIEH, MAHMOUD RIFAI, and MAHMOUD ELMIARI opened bank
`
`accounts for use by DAYTON PHARMACY to fund aspects of the conspiracy.
`
`57.
`
`During the course and in furtherance of the conspiracy, YOHANNES
`
`TINSAE and others were responsible for, and did, place orders to pharmaceutical
`
`companies to supply controlled substances to DAYTON PHARMACY, including to
`
`from SUPPLIER A, SUPPLIER B, and SUPPLIER C.
`
`58.
`
`In or around May 2012, SUPPLIER A, a pharmaceutical supplier,
`
`refused to continue to supply DAYTON PHARMACY with controlled substances.
`
`59.
`
`During the course and in furtherance of the conspiracy, in or around
`
`June 2012,
`
`ISMAIL ABUHANIEH applied to another pharmaceutical supplier,
`
`SUPPLIER B, to supply DAYTON PHARMACY with controlled substances.
`
`12
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 13 of 15 PAGEID #: 38
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 13 0f 15 PAGEID #: 38
`
`60.
`
`During the course and in furtherance of the conspiracy, in or around
`
`August 2014,
`
`to induce SUPPLIER B to continue to supply pharmaceuticals t0
`
`DAYTON PHARMACY, YOI—IANNES TINSAE, and others, made false statements
`
`to SUPPLIER B,
`
`to
`
`induce SUPPLIER B to
`
`sell
`
`controlled
`
`substance
`
`pharmaceuticals to DAYTON PHARMACY.
`
`61.
`
`During the course and in furtherance of the conspiracy, in or around
`
`January 2016,
`
`to induce SUPPLIER B to continue to supply pharmaceuticals to
`
`DAYTON PHARMACY, ISMAIL ABUHANIEH, MAHMOUD ELMIARI, and others,
`
`made false statements to SUPPLIER B, to induce SUPPLIER B to sell controlled
`
`substance pharmaceuticals to DAYTON PHARMACY.
`
`62.
`
`During the course and in furtherance of the conspiracy, in or around
`
`January 2017, MAHMOUD ELMIARI, and others, made false statements to a
`
`pharmaceutical supplier, SUPPLIER C,
`
`to induce SUPPLIER C to sell controlled
`
`substance pharmaceuticals to DAYTON PHARMACY.
`
`63.
`
`During the course and in furtherance of the conspiracy,
`
`ISMAIL
`
`ABUHANIEH, MAHMOUD RIFAI, MAHMOUD ELMIARI, YOHANNES TINSAE,
`
`and other conspirators known and unknown to the Grand Jury obtained substantial
`
`income and resources, and enriched themselves from the conspiracy to obtain
`
`controlled substances by misrepresentation,
`
`fraud,
`
`forgery,
`
`deception,
`
`and
`
`subterfuge.
`
`All in violation of Title 21, United States Code, Section 846.
`
`13
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 14 of 15 PAGEID #: 39
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 14 0f 15 PAGEID #: 39
`
`FORFEITURE ALLEGATION S
`
`The GRAND JURY further alleges:
`
`64.
`
`The allegations contained in Counts One through Eight of this
`
`Indictment are incorporated here for the purpose of alleging forfeiture pursuant to
`
`the provisions of Title 18, United States Code, Section 982.
`
`65.
`
`Upon conviction of a violation of Title 21, or United States Code,
`
`Sections 841, 846 or 856, as alleged in Counts One through Eight of this Indictment,
`
`the defendants shall forfeit to the United States, irrespective of any provision of
`
`State law
`
`a.
`
`any property, real or personal, that constitutes or is derived,
`
`directly or indirectly, as the result of such violation, including but not limited to the
`
`premises located at 301 West First Street, Suite 100, Dayton, Ohio; and
`
`b.
`
`any DEA license(s)
`
`for BROWN, ABUHANIEH, RIFAI,
`
`TINSAE, and ELMIARI;
`
`c.
`
`any of the defendants’ property used, or intended to be used, in
`
`any manner or part, to commit, or to facilitate the commission of, such violation.
`
`66.
`
`If any of the property described above as being subject to forfeiture, as
`
`a result of any act or omission of the defendants:
`
`i.
`
`ii.
`
`cannot be located upon the exercise of due diligence;
`
`has been transferred or sold to, or deposited With, a third party;
`
`iii.
`
`has been placed beyond the jurisdiction of the Court;
`
`iv.
`
`has been substantially diminished in value; or
`
`14
`
`

`

`Case: 3:19-cr-00068-WHR Doc #: 7 Filed: 04/09/19 Page: 15 of 15 PAGEID #: 40
`Case: 3:19-Cr-00068-WHR DOC #: 7 Filed: 04/09/19 Page: 15 0f 15 PAGEID #: 40
`
`V.
`
`has been commingled with other property that cannot be
`
`subdivided without difficulty;
`
`the defendants shall
`
`forfeit
`
`to the United States any other property of the
`
`defendant, up to the value of the property described above, pursuant to Title 21,
`
`United States Code, Section 853(p).
`
`All pursuant to Title 21, United States Code, Section 853(a).
`
`A TRUE BILL:
`
`C")
`
`FOR PERSON
`
`BENJAMIN C. GLASSMAN
`
`United States Attorney
`
`JOSEPH BEEMSTERBOER
`
`UNITED STATES DEPARTMENT OF JUSTICE
`
`CRIMINAL DIVISION, FRAUD SECTION
`DEPUTY CHIEF, HEALTH CARE FRAUD UNIT
`‘
`/
`
`
`
`
`
`LESLIE S. GARTHWA TE
`TOM TYNAN
`
`TRIAL ATTORNEYS
`
`UNITED STATES DEPARTMENT OF JUSTICE
`
`CRIMINAL DIVISION, FRAUD SECTION
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket